PropertyValue
?:abstract
  • The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.
?:creator
?:doi
  • 10.3760/cma.j.issn.1001-0939.2020.03.004
?:doi
?:journal
  • Zhonghua_jie_he_he_hu_xi_za_zhi_=_Zhonghua_jiehe_he_huxi_zazhi_=_Chinese_journal_of_tuberculosis_and_respiratory_diseases
?:license
  • unk
?:pmid
?:pmid
  • 32164080
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • [Potential antiviral therapeutics for 2019 Novel Coronavirus].
?:type
?:year
  • 2020-03-12

Metadata

Anon_0  
expand all